CN101850027B - Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof - Google Patents
Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof Download PDFInfo
- Publication number
- CN101850027B CN101850027B CN 200910081282 CN200910081282A CN101850027B CN 101850027 B CN101850027 B CN 101850027B CN 200910081282 CN200910081282 CN 200910081282 CN 200910081282 A CN200910081282 A CN 200910081282A CN 101850027 B CN101850027 B CN 101850027B
- Authority
- CN
- China
- Prior art keywords
- fructus
- radix
- pharmaceutical composition
- ligustri lucidi
- schisandrae chinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a pharmaceutical composition with functions of radiation resistance and immunity enhancement and a preparation method thereof. The composition is prepared with the following raw materials according to a certain weight ratio: ginseng, radix astragali, schisandra, rhodiola extract, fructus ligustri lucidi and medlar, and has the effects of radiation resistance and immunity enhancement.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition with radioprotective, enhancing immunity function and preparation method thereof.The invention belongs to field of health care food.
Background technology
Along with the progress of society, TV, computer, mobile phone being used more and more widely, they have also brought a large amount of electromagnetic radiation when bringing convenience to people.In addition, along with the development of medical and health care system, the application of radiotherapy chemotherapy and large-scale checkout facility also can bring electromagnetic radiation to the patient.Radiation can cause diseases such as headache, dizzy, weak, insomnia, hypomnesis, can cause also that seriously the leukocyte number reduces, thus malignant changes such as reduction body immunity.Therefore, the medicine that seek a kind ofly have radioprotective, strengthens the body immunity function is extremely important.
Summary of the invention
The invention provides a kind of new pharmaceutical composition, said composition has the function of radioprotective, enhancing immunity.
Another object of the present invention provides the preparation method of aforementioned pharmaceutical compositions.
The present invention is achieved by the following technical solutions:
The present invention is made by the following weight parts proportion raw material:
Radix Ginseng 3-15 part, Radix Astragali 15-50 part, Fructus Schisandrae Chinensis 10-40 part, Radix Rhodiolae extract 5-30 part, Fructus Ligustri Lucidi 5-20 part, Fructus Lycii 8-20 part.
The preferred weight portion proportioning of described pharmaceutical composition is:
Radix Ginseng 4-7 part, Radix Astragali 20-30 part, Fructus Schisandrae Chinensis 15-20 part, Radix Rhodiolae extract 10-20 part, Fructus Ligustri Lucidi 7-15 part, Fructus Lycii 10-18 part.
Preparation of drug combination method of the present invention is as follows:
Get Radix Ginseng, the Radix Astragali, Fructus Schisandrae Chinensis, Radix Rhodiolae extract, Fructus Ligustri Lucidi, Fructus Lycii in proportion, decoct with water, merge extractive liquid, concentrates, and adds appropriate amount of auxiliary materials, makes pharmaceutically acceptable oral formulations.
Pharmaceutical composition preferred manufacturing procedure of the present invention is as follows:
Get Radix Ginseng, the Radix Astragali, Fructus Schisandrae Chinensis, Radix Rhodiolae extract, Fructus Ligustri Lucidi, Fructus Lycii in proportion, adding for the first time 10 times of water gagings extracted 2 hours, adding for the second time 8 times of water gagings extracted 1.5 hours, adding 6 times of water gagings for the third time extracted 1.5 hours, merge extractive liquid,, being concentrated into relative density is 1.10-1.15, is about 60% to wherein adding ethanol to containing the alcohol amount then, stir, centrifugal, collect supernatant, concentrating under reduced pressure reclaims ethanol, add correctives, antiseptic then, mix homogeneously, ultrafiltration, sterilization, fill makes oral liquid.
In pharmaceutical composition of the present invention, the mechanism of action of each medicine is as follows:
Radix Ginseng: contain ginsenoside, nitrogen-containing compound, organic acid, polysaccharide and other multiple active components.Modern pharmacology shows that ginsenoside and ginseng polysaccharide can significantly improve body immunity, and the hemopoietic function of bone marrow is had protection and stimulation, also has antitumor, the anti-ageing effect of waiting for a long time.
The Radix Astragali: its main chemical compositions has saponin, polysaccharide etc.Modern pharmacological research shows, the Radix Astragali has effects such as diuresis, blood pressure lowering, antibiotic, radioprotective, enhancing immunity.
Fructus Schisandrae Chinensis: the peel of Fructus Schisandrae Chinensis and ripe the kind in the skin contain lignanoid, are the effective medicinal components of Fructus Schisandrae Chinensis, comprising multiple schizandrin, can promote body metabolism, share with Radix Ginseng, the Radix Astragali, strengthen the human body immunity.
Radix Rhodiolae: be Tibetan medicine commonly used, main effective ingredient is rhodioside, polysaccharide, protein, flavone compound, alkaloid etc.Modern pharmacological research shows that Radix Rhodiolae extract has effects such as the immunity of organisms of raising, resisting fatigue, anti-hypoxia, radioprotective, antiviral, preventing tumor.
Fructus Ligustri Lucidi: its active component has oleanolic acid, Fructus Ligustri Lucidi polysaccharide etc.Modern study proves the function of the cellular immunization that is significantly improved and improves the effect of life quality that also the leukopenia that chemicotherapy is caused has the rising effect, stimulates hemopoietic function of bone marrow, improves and promote hematopoietic function.
Fructus Lycii: its chemical constituent mainly contains lycium barbarum polysaccharide, betanin, carotenoid and various trace elements.Studies show that lycium barbarum polysaccharide has the effect that promotes immunity, also have and alleviate the leukopenia that causes because of chemicotherapy that adjust patient's immunocyte ratio, radioprotective etc. are effect significantly.
Below example illustrates beneficial effect of the present invention by experiment:
Experimental example:
1, main material
Animal: the ICR female mice, body weight 20-22g is provided by Military Medical Science Institute's Experimental Animal Center.
Irradiation capsule: wooden 30cm * 16cm * 3cm, base plate is fixed with iron sheet, be separated into 10 small rectangle spaces with iron sheet in the box, a mice is closed in each space, cover plate adopts the lucite of 1mm thickness, be with holes in each position, space, for mouse breathing, this lucite can be movable arbitrarily in chute.
Illuminate condition: accelerator, the X line, 10MEV, dosage 6GY, whole body shines together, range 100cm.
Instrument: 754-ultraviolet-uisible spectrophotometer.
Tried thing: the oral liquid of being made by pharmaceutical composition of the present invention.
2, experimental technique
Select 50 of healthy ICR mices, body weight 20-22g, female, nursing conformed in 4 days in laboratory animal room, numeration of leukocyte and classification are carried out in afterbody blood sampling in the 5th day, mice is divided equally 5 groups at random after recording normal data, 10 every group, positive controls (I), model group (II), oral liquid high dose group of the present invention (III), low dose group (IV), normal control group (V).(I) group press 45mg/kg dosage ig SHENGBAIAN PIAN, (III) and (IV) group ig oral liquid 0.4ml of the present invention, 0.2ml respectively, and (II) and (V) group difference ig distilled water 0.4ml, once a day.The feed of freely drinking water of experimental session mice, (I), (II), (III), (IV) group are carried out roentgen radiation x after ig5 days, each group is carried out ig later on, tracing observation leukocyte situation of change, each group is got half mouse assay serum hemolysin after 30 days, and second half measures macrophage phagocytic function, puts to death at last and weighs, spleen, thymus are got in dissection, calculate its internal organs Body Mass Index.
3, observation index
3.1 total white blood cells, the lymphocyte absolute number
3.2 serum hemolysin is measured
3.3 macrophage phagocytic function is measured
Phagocytic percentage: engulf macrophage number/200 * 100% of chicken red blood cell, phagocytic index: the average of each macrophage phagocytic chicken red blood cell.
3.4 spleen, thymus index: spleen, thymic weight mg/ body weight g
4, experimental result
4.1 oral liquid of the present invention is to the influence of roentgen radiation x murine interleukin sum and lymphocyte absolute number.Mice total white blood cells and lymphocyte absolute number behind the 6GY roentgen radiation x descend immediately, reduced as far as possible in the 3rd day according to the back, but the experimental group fall of ig oral liquid of the present invention are significantly less than model group, significant difference.Each irradiation group murine interleukin number begins to recover after 3 days, and the resume speed of the experimental group of ig oral liquid of the present invention is obviously faster than model group, and the most obvious with lymphocyte, returns to the pre-irradiation level after ten days.Normal control group total white blood cells and lymphocyte number in whole experiment are not seen significant change.Observe from whole experiment, illustrate that oral liquid of the present invention has the certain protection effect to the murine interleukin damage that roentgen radiation x causes.
4.2 oral liquid of the present invention is to the influence of roentgen radiation x mice serum hemolysin: see Table 1.
Table 1 oral liquid of the present invention to roentgen radiation x after the influence (X ± s) of mice serum hemolysin
| Group | Animal (only) | Dosage | Hemolysin content (OD) |
| I | 5 | Berbamine 45mg/kg | 2.159±0.102 |
| II | 5 | Distilled water 0.4ml | 1.611±0.408 |
| III | 5 | Oral liquid 0.4ml of the present invention | 2.307±0.064 |
| IV | 5 | Oral liquid 0.2ml of the present invention | 1.924±0.227 |
| V (normal control group) | 5 | Distilled water 0.4ml | 2.894±0.521 |
By table 1 as seen, shine the serum hemolysin content of the mice of ig oral liquid of the present invention after 30 days apparently higher than model group, there were significant differences for high dose group.
4.3 oral liquid of the present invention is to the influence of roentgen radiation x Turnover of Mouse Peritoneal Macrophages phagocytic function: see Table 2.
Table 2 oral liquid of the present invention is to the influence of roentgen radiation x Turnover of Mouse Peritoneal Macrophages phagocytic function (X ± s)
| Group | Animal (only) | Dosage | Engulf (%) | Phagocytic index |
| I | 5 | Berbamine 45mg/kg | 20.1±5.7 | 0.35±0.22 |
| II | 5 | Distilled water 0.4ml | 11.9±5.5 | 0.20±0.13 |
| III | 5 | Oral liquid 0.4ml of the present invention | 28.8±9.6 | 0.47±0.21 |
| IV | 5 | Oral liquid 0.2ml of the present invention | 19.4±6.2 | 0.33±0.09 |
| V (normal control group) | 5 | Distilled water 0.4ml | 45.1±3.4 | 0.58±0.16 |
By table 2 as seen; after mice was subjected to roentgen radiation x, the peritoneal macrophage phagocytic function obviously reduced, and obviously was better than model group but ig tries its phagocytic function of mice of thing; significant difference illustrates that being tried thing damages the protective effect that any is arranged to the macrophage phagocytic function that roentgen radiation x causes.
4.4 tried thing to the influence of roentgen radiation x mouse spleen, thymic weight index: see Table 3.
Table 3 is tried thing to the influence of roentgen radiation x mouse spleen, thymic weight index (X ± s)
| Rank | Animal (only) | Dosage | Index and spleen index | Thymus index |
| I | 10 | Berbamine 45mg/kg | 4.52±0.41 | 1.68±0.61 |
| II | 10 | Distilled water 0.4ml | 4.47±0.53 | 1.53±0.47 |
| III | 10 | Oral liquid 0.4ml of the present invention | 4.75±1.04 | 1.79±0.38 |
| IV | 10 | Oral liquid 0.2ml of the present invention | 4.71±1.98 | 1.64±0.55 |
| V (normal control group) | 10 | Distilled water 0.4ml | 5.39±0.55 | 2.41±0.83 |
By table 3 as seen, mice spleen, thymus index and normal control group after shining relatively are atrophy trend, and spleen, thymus index that ig is tried the thing mice are higher than model group, and increase and the index increase with dosage.
Above experimental result shows that the present composition has radioprotective, the effect of raise immunity.
Concrete embodiment
Below by the specific embodiment, foregoing of the present invention is described in further detail.
Embodiment 1:
Get 5 parts of Radix Ginsengs, 25 parts of the Radixs Astragali, 18 parts of Fructus Schisandrae Chinensis, 15 parts of Radix Rhodiolae extracts, 10 parts of Fructus Ligustri Lucidi, 15 parts of Fructus Lycii, adding for the first time 10 times of water gagings extracted 2 hours, adding for the second time 8 times of water gagings extracted 1.5 hours, adding 6 times of water gagings for the third time extracted 1.5 hours, merge extractive liquid,, being concentrated into relative density is 1.10-1.15, is about 55% to wherein adding ethanol to containing the alcohol amount then, stir, centrifugal, collect supernatant, concentrating under reduced pressure reclaims ethanol, add correctives, antiseptic then, mix homogeneously, ultrafiltration, sterilization, fill makes oral liquid.
Embodiment 2:
Get 7 parts of Radix Ginsengs, 22 parts of the Radixs Astragali, 15 parts of Fructus Schisandrae Chinensis, 17 parts of Radix Rhodiolae extracts, 8 parts of Fructus Ligustri Lucidi, 18 parts of Fructus Lycii, adding for the first time 10 times of water gagings extracted 2 hours, adding for the second time 8 times of water gagings extracted 1.5 hours, adding 6 times of water gagings for the third time extracted 1.5 hours, merge extractive liquid,, being concentrated into relative density is 1.10-1.15, is about 55% to wherein adding ethanol to containing the alcohol amount then, stir, centrifugal, collect supernatant, concentrating under reduced pressure reclaims ethanol, add correctives, antiseptic then, mix homogeneously, ultrafiltration, sterilization, fill makes oral liquid.
Claims (5)
1. pharmaceutical composition with radioprotective, enhancing immunity function, it is characterized in that this pharmaceutical composition is to be made by following bulk drugs: Radix Ginseng 3-15 part, Radix Astragali 15-50 part, Fructus Schisandrae Chinensis 10-40 part, Radix Rhodiolae extract 5-30 part, Fructus Ligustri Lucidi 5-20 part, Fructus Lycii 8-20 part.
2. pharmaceutical composition according to claim 1, it is characterized in that this pharmaceutical composition is to be made by following bulk drugs: Radix Ginseng 4-7 part, Radix Astragali 20-30 part, Fructus Schisandrae Chinensis 15-20 part, Radix Rhodiolae extract 10-20 part, Fructus Ligustri Lucidi 7-15 part, Fructus Lycii 10-18 part.
3. claim 1 or 2 described preparation of drug combination methods is characterized in that this method is:
Get Radix Ginseng, the Radix Astragali, Fructus Schisandrae Chinensis, Radix Rhodiolae extract, Fructus Ligustri Lucidi, Fructus Lycii in proportion, decoct with water, merge extractive liquid, concentrates, and adds appropriate amount of auxiliary materials, makes pharmaceutically acceptable oral formulations.
4. according to the described preparation of drug combination method of claim 3, it is characterized in that this method is:
Get Radix Ginseng, the Radix Astragali, Fructus Schisandrae Chinensis, Radix Rhodiolae extract, Fructus Ligustri Lucidi, Fructus Lycii in proportion, adding for the first time 10 times of water gagings extracted 2 hours, adding for the second time 8 times of water gagings extracted 1.5 hours, adding 6 times of water gagings for the third time extracted 1.5 hours, merge extractive liquid,, being concentrated into relative density is 1.10-1.15, is 55% to wherein adding ethanol to containing the alcohol amount then, stir, centrifugal, collect supernatant, concentrating under reduced pressure reclaims ethanol, add correctives, antiseptic then, mix homogeneously, ultrafiltration, sterilization, fill makes oral liquid.
5. claim 1 or 2 described pharmaceutical compositions are for the preparation of the application in the medicine of radioprotective, enhancing immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910081282 CN101850027B (en) | 2009-03-31 | 2009-03-31 | Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910081282 CN101850027B (en) | 2009-03-31 | 2009-03-31 | Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101850027A CN101850027A (en) | 2010-10-06 |
| CN101850027B true CN101850027B (en) | 2013-08-28 |
Family
ID=42801817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910081282 Active CN101850027B (en) | 2009-03-31 | 2009-03-31 | Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101850027B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107812066A (en) * | 2017-11-08 | 2018-03-20 | 贾京达 | A kind of pharmaceutical composition of Antiradiation injury and preparation method thereof |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102860510A (en) * | 2012-10-09 | 2013-01-09 | 三普药业股份有限公司 | Anti-fatigue anti-anoxia health food and preparation method thereof |
| CN103142760A (en) * | 2013-04-01 | 2013-06-12 | 通化百泉保健食品有限公司 | Ginseng Yangyuanbao tablet and preparation method thereof |
| CN105194083B (en) * | 2015-09-22 | 2019-11-12 | 长春中医药大学 | A kind of strengthen immunity and anti-radiation medicine composite and preparation method thereof |
| CN107308317B (en) * | 2017-06-20 | 2020-05-15 | 甘肃中医药大学 | Traditional Chinese medicine composition for preventing and treating radiation damage |
| CN109223973B (en) * | 2017-07-11 | 2021-09-10 | 四川省中医药科学院 | Radiation-proof composition and preparation method and application thereof |
| CN107853570A (en) * | 2017-12-09 | 2018-03-30 | 党亮才 | A kind of anti-aging medicine congee of radioresistance and preparation method thereof |
| CN108066599B (en) * | 2017-12-28 | 2020-08-21 | 神威药业集团有限公司 | Composition for enhancing immunity and assisting in radiation resistance and preparation method and application thereof |
| CN114847420A (en) * | 2022-04-29 | 2022-08-05 | 山东美果来食品有限公司 | Pomegranate and ginseng beverage with antioxidant and anti-aging functions |
| CN116440204B (en) * | 2023-04-26 | 2024-01-30 | 江西维莱营健高科有限公司 | Capsule with immunity enhancing function and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086137A (en) * | 1993-01-01 | 1994-05-04 | 黄标春 | A kind of raise immunity anti-radiation medicine composite |
| CN1528209A (en) * | 2003-09-29 | 2004-09-15 | �������¿��汣��ʳƷ����˾ | Health-care food with immune modulation and cltiradiation function and preparing method thereof |
-
2009
- 2009-03-31 CN CN 200910081282 patent/CN101850027B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086137A (en) * | 1993-01-01 | 1994-05-04 | 黄标春 | A kind of raise immunity anti-radiation medicine composite |
| CN1528209A (en) * | 2003-09-29 | 2004-09-15 | �������¿��汣��ʳƷ����˾ | Health-care food with immune modulation and cltiradiation function and preparing method thereof |
Non-Patent Citations (10)
| Title |
|---|
| > * |
| < * |
| .2008,第11卷(第4期),238-240. * |
| .2008,第17卷(第4期),511-512. * |
| 中国辐射卫生> * |
| 实用药物与临床> * |
| 赵红等.抗辐射中药的研究现状及进展.< * |
| 赵红等.抗辐射中药的研究现状及进展.<<实用药物与临床>>.2008,第11卷(第4期),238-240. |
| 黄德娟等.天然抗辐射物质抗损伤作用研究进展.< * |
| 黄德娟等.天然抗辐射物质抗损伤作用研究进展.<<中国辐射卫生>>.2008,第17卷(第4期),511-512. |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107812066A (en) * | 2017-11-08 | 2018-03-20 | 贾京达 | A kind of pharmaceutical composition of Antiradiation injury and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101850027A (en) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101850027B (en) | Pharmaceutical composition with functions of radiation resistance and immunity enhancement and preparation method thereof | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN103735825A (en) | Comprehensive conditioning traditional Chinese medicine composition and application thereof | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| Jang et al. | Immune-modulating activity of extract prepared from mycelial culture of Chinese caterpillar mushroom, Ophiocordyceps sinensis (Ascomycetes) | |
| Xu et al. | The versatile functions of G. Lucidum polysaccharides and G. Lucidum triterpenes in cancer radiotherapy and chemotherapy | |
| Chen et al. | Protective effect of Ganoderma (Lingzhi) on radiation and chemotherapy | |
| CN102861193A (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN103356732A (en) | Pharmaceutical composition for preventing and treating hepatic fibrosis or nonalcoholic fatty liver disease | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN102872385B (en) | Compound Chinese medicinal composition for treating advanced gastric cancer and preparation method and application thereof | |
| CN102125571A (en) | Dammarane aglycon compound and application thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN1911329B (en) | Traditional Chinese medicine composition for preventing and/or adjuvant therapy of malignant tumor | |
| CN101422534B (en) | Radio therapy sensitization composite preparation | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| Brigham et al. | Cordyceps (Cordyceps spp.): an evidence-based systematic review by the Natural Standard Research Collaboration | |
| CN102362893B (en) | Ganoderma lucidum-chrysanthemum capsule for improving sleep and preparation method thereof | |
| CN1951449B (en) | Medicament for increasing peripheral blood leukocyte and use thereof | |
| CN102526370A (en) | Cordyceps preparation for promoting immunity of human body and preparation method thereof | |
| CN101049344B (en) | Pharmaceutical composition of Qishen in use for treating leucopenia, and preparation method | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof | |
| CN105079160B (en) | A kind of blood tonifying compound and preparation method thereof | |
| CN1421227A (en) | Medicine for preventing and treating radiative damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHUHAI BAODE RUNSHENG HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150320 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 XICHENG, BEIJING TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee after: Zhuhai Bao Derun Health Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Increase Pharmaceutical Technology Co., Ltd. |